Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Revenue (2016 - 2025)

IGC Pharma has reported Revenue over the past 16 years, most recently at $191000.0 for Q3 2025.

  • Quarterly Revenue fell 53.64% to $191000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Sep 2025, down 6.51% year-over-year, with the annual reading at $1.3 million for FY2025, 5.5% down from the prior year.
  • Revenue was $191000.0 for Q3 2025 at IGC Pharma, down from $328000.0 in the prior quarter.
  • Over five years, Revenue peaked at $555000.0 in Q2 2023 and troughed at $56000.0 in Q3 2021.
  • The 5-year median for Revenue is $212000.0 (2022), against an average of $238157.9.
  • Year-over-year, Revenue crashed 86.82% in 2021 and then soared 260.71% in 2022.
  • A 5-year view of Revenue shows it stood at $142000.0 in 2021, then surged by 133.8% to $332000.0 in 2022, then crashed by 38.55% to $204000.0 in 2023, then increased by 25.98% to $257000.0 in 2024, then fell by 25.68% to $191000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Revenue are $191000.0 (Q3 2025), $328000.0 (Q2 2025), and $330000.0 (Q1 2025).